glp-1 agonists reduce inflammation receptor and next-generation metabolic hormone therapies in chronic kidney disease Glucagon-like peptide-1: a multi-faceted anti-inflammatory

Early studies show up to 13% body weight reduction in three months

In FLOW, semaglutide improved kidney outcomes in patients with type 2 diabetes and chronic kidney disease. What GLP-1 and GLP-1/GIP Medications Do Not Do 1) They Do NOT Treat Autoimmune Disorders Autoimmune diseases involve immune-system pathways such as T-cell activation, autoantibody production, complement activation, and immune cytokine dysregulation

Commentary: The expanding benefits of GLP-1 medicines

It does the same actions in the body, helping lower blood sugar and make you less hungry, but its effects are amplified

The FDA also recommends examining hard clinical endpoints such hepatic decompensations, transplant free survival, and all-cause mortality, although these results are not necessarily needed prior to drug approval given the long length of follow up potentially required

Perry Wilson wrote